A Phase 3 interventional study of insulin degludec/liraglutide and insulin glargine in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 91 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-01-03.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 12th largest by enrollment, is one of 8 that started in 2013, is one of 49 in phase 3, and was the 38th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 8 started in 2013.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 557 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 83rd largest by enrollment of the 428 interventional ones that give a count, is one of 33 that started in 2013, is one of 187 in phase 3, and was the 361st registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of the trial is to compare the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 557 is above the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Inclusion Criteria: - Type 2 diabetes mellitus - 7.0-10.0% [53-86 mmol/mol] (both inclusive) by central laboratory analysis - Current treatment with insulin glargine for at least 90 days prior to screening - Stable daily dose of insulin glargine between 20 units and 50 units (both inclusive) for at least 56 days prior to screening. Total daily dose should be within the range of 20-50 units, both inclusive, on the day of screening, but individual fluctuations of plus/minus 10 procent within the 56 days prior to screening are acceptable - Stable daily dose of metformin (above or equal to 1500 mg or max tolerated dose) for at least 90 days prior to screening - (BMI) below or equal to 40 kg/m\^2 Exclusion Criteria: - Any use of oral antidiabetic agents (OADs) (except for metformin) within 90 days prior to Visit 1 (screening) - Current use of any drug (except metformin and insulin glargine) or anticipated change inconcomitant medication, which in the investigator's opinion could interfere with the glucose metabolism (e.g. systemic ) - Previous and/or current treatment with any insulin regimen other than basal insulin, e.g. prandial or pre-mixed insulin (short term treatment due to intercurrent illness includinggestational diabetes is allowed at the discretion of the investigator) - Previous and/or current treatment with glucagon-like peptide-1 (GLP-1) receptor agonists (e.g. exenatide, liraglutide) - Impaired liver function, defined as ALAT () above or equal to 2.5 times upper normal range (UNR) - Impaired renal function defined as serum-creatinine above or equal to 133 micromol/L (above or equal to 1.5 mg/dL) for males and above or equal to 125 micromol/L (1.4 mg/dL) for females, or as allowed according to local for metformin - Screening calcitonin above or equal to 50 ng/L - Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) - History of chronic pancreatitis or idiopathic acute pancreatitis
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/liraglutide
Drug: insulin glargine
Drug pages: Insulin degludec · Liraglutide
Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Change from baseline in HbA1c after 26 weeks of treatment
Time frame: Week 0, week 26
Change From Baseline in Body Weight
Change from baseline in body weight after 26 weeks of treatment
Time frame: Week 0, week 26
Number of Treatment Emergent Confirmed Hypoglycaemic Episodes
Confirmed hypoglycaemic episodes were defined as either: Severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or an episode biochemically confirmed by a plasma glucose value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.
Time frame: During 26 weeks of treatment
The trial was conducted at 75 sites in 10 countries as follows: Argentina: 5 sites; Australia: 4 sites; Greece: 6 sites, Hungary: 4 sites; Mexico: 5 sites, Russian Federation: 11 sites; Slovakia: 11 sites, South Africa: 4 sites; Spain: 6 sites, United States: 19 sites.
| Milestone | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) |
|---|---|---|
| Started | 278 | 279 |
| Completed | 250 | 265 |
| Not completed | 28 | 14 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Death | 0 | 1 |
| Withdrew: Adverse event | 9 | 0 |
| Withdrew: Withdrawal criteria | 16 | 11 |
| Withdrew: Unclassified | 1 | 1 |
Change from baseline in HbA1c after 26 weeks of treatment
| Percentage (%) | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) |
|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) | -1.81 ± 1.08 | -1.13 ± 0.98 |
Change from baseline in body weight after 26 weeks of treatment
| Kg | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) |
|---|---|---|
| Change From Baseline in Body Weight | -1.4 ± 3.5 | 1.8 ± 3.6 |
Confirmed hypoglycaemic episodes were defined as either: Severe (i.e., an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions) or an episode biochemically confirmed by a plasma glucose value of \<3.1 mmol/L (56 mg/dL), with or without symptoms consistent with hypoglycaemia.
| Number of episodes | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) |
|---|---|---|
| Number of Treatment Emergent Confirmed Hypoglycaemic Episodes | 289 | 683 |
Collected over Week 0 to week 27 (26-week treatment period and a follow-up visit 1 week after end of treatment). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Insulin Degludec/Liraglutide (IDegLira) | — | 5/278 (1.8%) | 52/278 (18.7%) |
| Insulin Glargine (IGlar) | — | 9/279 (3.2%) | 22/279 (7.9%) |
| Event | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) |
|---|---|---|
| CholelithiasisHepatobiliary disorders | 1/278 | 0/279 |
| Postmenopausal haemorrhageReproductive system and breast disorders | 1/278 | 0/279 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/278 | 0/279 |
| Rectal adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/278 | 0/279 |
| Vertebrobasilar insufficiencyNervous system disorders | 1/278 | 0/279 |
| Acute coronary syndromeCardiac disorders | 0/278 | 1/279 |
| AppendicitisInfections and infestations | 0/278 | 1/279 |
| ArrhythmiaCardiac disorders | 0/278 | 1/279 |
| Auricular perichondritisEar and labyrinth disorders | 0/278 | 1/279 |
| Biliary colicHepatobiliary disorders | 0/278 | 1/279 |
| Event | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) |
|---|---|---|
| NauseaGastrointestinal disorders | 26/278 | 3/279 |
| DiarrhoeaGastrointestinal disorders | 20/278 | 7/279 |
| VomitingGastrointestinal disorders | 14/278 | 5/279 |
| HeadacheNervous system disorders | 11/278 | 14/279 |
Full analysis set (FAS) was used for baseline measurements. FAS included all randomised subjects.
| Age, Continuous(Years) | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) | Total |
|---|---|---|---|
| Mean | 58.4 ± 9.8 | 59.1 ± 9.3 | 58.8 ± 9.5 |
| Sex: Female, Male(Participants) | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) | Total |
|---|---|---|---|
| Female | 135 | 142 | 277 |
| Male | 143 | 137 | 280 |
| Glycated hemoglobin (HbA1c)(Percentage (%)) | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) | Total |
|---|---|---|---|
| Mean | 8.4 ± 0.9 | 8.2 ± 0.9 | 8.3 ± 0.9 |
| Body weight(Kg) | Insulin Degludec/Liraglutide (IDegLira) | Insulin Glargine (IGlar) | Total |
|---|---|---|---|
| Mean | 88.3 ± 17.5 | 87.3 ± 15.8 | 87.8 ± 16.6 |
Ran from Sep 2013 to primary completion in Nov 2014, 13 months.
Results were first posted in Jan 2017, 2 years 2 months after primary completion. A results delay was requested in Oct 2016.
Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 13 months is below that.
Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide